
Betagan0.5%
Eskayef Bangladesh Ltd.
Levobunolol is a non-selective beta-adrenergic blocking agent formulated as an ophthalmic (eye) solution.
Levobunolol is a non-selective beta-adrenergic blocking agent formulated as an ophthalmic (eye) solution. It is FDA-approved for the following uses:
Levobunolol may also be used as adjunctive therapy in combination with other IOP-lowering agents (for example, prostaglandin analogues or carbonic anhydrase inhibitors) when a single agent does not adequately control intraocular pressure. Levobunolol is not indicated as monotherapy for acute angle-closure glaucoma and is not an antibiotic or anti-infective agent.
| Indication | Dose |
|---|---|
| Chronic open-angle glaucoma / ocular hypertension (adults) | One drop of Levobunolol 0.5% solution in the affected eye(s) once daily; some patients may require one drop twice daily if IOP is not adequately controlled with once-daily dosing. |
| Lower-strength formulation | One drop of Levobunolol 0.25% solution in the affected eye(s) once or twice daily, as directed by the physician. |
Use Levobunolol exactly as directed by the prescribing physician. If more than one topical ophthalmic medication is being used, administer them at least 5 minutes apart. For instillation technique, see Administration below.
The most common effect of Levobunolol is transient ocular burning and stinging upon instillation (reported in up to about 1 in 3 patients), and blepharoconjunctivitis (in up to about 1 in 20 patients).
Less common effects reported with Levobunolol include:
Levobunolol is contraindicated in patients with:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.